SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia. Ruxolitinib (1.5%) cream is a novel, topical Janus kinase (JAK) inhibitor.[1] In the U.S., OPZELURA is indicated for the t

90% freedom from atrial arrhythmias at six months with neuromodulation vs. 80.8% with sham Randomized, double-blind, sham-controlled results presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in peer-reviewed Heart Rhythm ATLANTA and LOS ANGELES, Sept. 20, 2026 /PRNewswire/ -- StimCardio Medical today announced positive results from the randomized, double-blind, sham-controlled NeuroPulse pilot study evaluating non-invasive median nerve stimulation (MNS)

Late-breaking HRX data advance Field Medical's "instantaneous ablation" workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System ATLANTA and CARLSBAD, Calif., Sept. 20, 2026 /PRNewswire/ -- Field Medical, Inc. , advancing high-voltage focal pulsed field ablation (PFA) for complex arrhythmias, today announced publication of 12-month results from the first-in-human Field PULSE trial in JACC: Clinical Electrophysiology. The findings were presented simult

National campaign features ESPN broadcaster and cervical cancer survivor Erin Andrews alongside leading women's cancer organizations and experts NEW YORK, Sept. 20, 2026 /PRNewswire/ -- Mediaplanet today announces the national launch of its Women vs. Cancer campaign, publishing Sunday, September 20, within the Los Angeles Times. The campaign brings together leading voices in women's cancer to raise awareness around symptoms, earlier detection, advances in treatment and the importance of women ad

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological differenceCue Biopharma to host conference

NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical trial of AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC). About the Phase IIb Study The Phase IIb study is a multicenter, double-blind, placebo-controlled clinical

Today, a brief rundown of news involving Ultragenyx and Bristol Myers Squibb, as well as updates from Roche, Longeveron and Rocket Pharmaceuticals that you may have missed.The Food and Drug Administration has approved the first gene therapy for the rare progressive neurological condition Sanfilippo syndrome Type A. Called Fayuvi and priced at $3.95 million, the treatment is now the second gene therapy Ultragenyx Pharmaceuticals has brought to market since August. Neither of those therapies are p

New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout expected Q1 2027 The Company has voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies; patients currently enrolled in the ongoing studies remain active Confe

Interactive research explorer helps users search scientific literature by condition, study type, light source and other criteriaDEURNE, Netherlands, Sept. 19, 2026 (GLOBE NEWSWIRE) -- NorahLux has launched the Red Light Therapy Research Hub, an interactive research tool designed to make studies on photobiomodulation easier to search and explore. The Photobiomodulation Research Explorer provides access to 10,022 scientific studies covering red and near-infrared light therapy. The tool allows v

SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- A news report from Yicai Global: On September 17, the BioShanghai Week 2026 opened at Zhangjiang Science Hall in Shanghai. Themed "AI for Biopharma, Health for All," this year's event brings together innovation resources from around the world to foster an open, collaborative innovation ecosystem for the biopharmaceutical industry. Continue Reading Yicai Global The opening ceremony marked the launch of the "Connect Globally: Shanghai–London Life Sciences